Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
Lowering low-density lipoprotein cholesterol plays an important role in therapeutic strategies designed to reduce cardiovascular risk. However, the residual clinical risk in statin trials suggests that additional therapies will be required to achieve more effective prevention of cardiovascular disease. The high prevalence of hypertriglyceridemia and low levels of high-density lipoprotein cholesterol in diabetes presents further targets for the development of new cardioprotective therapies.